Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-MAD7, other undisclosed
Funding stage: Private
Location: Cambridge, MA, USA
Hunterian Medicine aims to enable CRISPR delivery within the limited AAV packaging capacity that currently represents one of the major challenges within therapeutic genome editing. The company is exploring a range of diseases and orphan indications for licensing and/or development, although it has yet to disclose targets and indications for its lead therapeutic programme.